Arch Biopartners Inc. ACHFF

Company Overview

Arch Biopartners Inc. is a Canadian biotechnology company focused on the development of therapies targeting inflammation, organ injury, and infectious disease complications. The company operates primarily in the biopharmaceutical industry, with a strategic emphasis on treatments for acute kidney injury, sepsis-related complications, and inflammatory lung disease. Its core value driver is the development and commercialization potential of its lead drug platform, cilastatin-based therapeutic candidates, particularly LSALT peptide technology and the drug candidate Metablok. The company’s activities are concentrated in drug research, clinical development, intellectual property management, and strategic licensing opportunities.

The company traces its origins to a biotechnology and engineering-focused business model before transitioning toward therapeutic drug development centered on novel peptide and small-molecule technologies. Over time, Arch Biopartners evolved into a clinical-stage biotechnology company focused on targeting the dipeptidase-1 (DPEP1) pathway, which it believes plays a role in inflammatory injury and vascular leakage syndromes. Its positioning is differentiated by its ownership of proprietary intellectual property surrounding DPEP1 inhibition and kidney-protective applications of cilastatin derivatives.